Physician profile
Sara Wong
NPI 1699062216
$1,378.11
in general payments reported to CMS, 2019-2025
14 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $141 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.13 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $265.10 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $254.93 | 2025 | Dupixent |
| Abbvie INC. | $166.49 | 2024-2025 | |
| Janssen Biotech, INC. | $150.14 | 2025 | Tremfya |
| Amgen INC. | $97.39 | 2024-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Incyte Corporation | $91.76 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $52.72 | 2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $45.51 | 2025 | |
| Pfizer INC. | $44.02 | 2024-2025 | |
| Verrica Pharmaceuticals INC. | $36.24 | 2024-2025 | Ycanth |
| Galderma Laboratories, L.P. | $35.54 | 2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $22.71 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $20.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.